Getinge announces date of 2015 Q2 report and conference call

Getinge will issue its Q2 report for 2015 on Wednesday July 15th 2015 at 08:00
CET, followed by a conference call at 10:00 CET, hosted by Alex Myers, CEO, and
Ulf Grunander, CFO.

We invite fund managers, analysts and the media to participate in the conference
call. Please see below details to join the conference:

Swedish dial in number: +46 (0) 8 5033 6539

UK dial in number: +44 (0) 20 3427 1916

US dial in number: +1 212 444 0895

Participant passcode: 6769502

Agenda

09:45 Call in to the conference

10:00 Review of the Q2 report

10:20 Q&A

11:00 End of conference

Two hours after the end of the conference call, a recorded version of the
conference can be accessed for 5 working days on the following number:

Sweden: +46 (0) 8 5051 3897

UK: +44 (0) 20 3427 0598

US: +1 347 366 9565

Code: 6769502

During the telephone conference a presentation will be held. To access the
presentation, please use this link:
http://www.livemeeting.com/cc/premconfeurope/join?id=6769502&role=attend&pw=pw48
8 
9

Alternatively enter the Live Meeting site and log into your meeting using the
Meeting ID and Password below:

Live Meeting: https://www.livemeeting.com/cc/premconfeurope/

Your Name: (Enter your name)

Web Meeting ID: 6769502

Web Meeting Password: pw4889

For more information, please contact:

Kornelia Rasmussen, Head of Group Communications

Phone: +46 (0)10 335 5810

E-mail: kornelia.rasmussen@getinge.com

Getinge Group is a global leading medical technology company that operates in
the areas of surgery, intensive care, infection control, care ergonomics and
wound care. Getinge Group has nearly 16,000 employees in over 40 countries and
generates sales of almost SEK 27 billion (2014). The Group is divided into three
business areas: Medical Systems, Extended Care and Infection Control and
operates under the brands of Maquet, ArjoHuntleigh and Getinge.

The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.